Moshe Mizrahy: Okay. Well, I believe the Empower is growing. The Empower sales is growing. We will not release numbers exactly because it’s now we’re not yet ready to do it. But we see some growth on the Empower platform as well. Regarding the indication for SUI, we have a discussion with the FDA on the protocol. They asked us to do some additional proof of concept study, which we’re doing right now in Columbia. We will come back to them with the results to finalize the protocol, hopefully before the end of the year. And then we will file an IRB to do the study in the United States, with of course approval of the FDA we will conduct the study. So I believe we should not see — we will not see any clearance before sometime to the end of 2024, but we do have clearance on the Viton for all kind of women health indication on the platforms and currently we are marketing the platforms with those indication.
In addition we are developing additional handpiece for the empower, which again now we are doing some proof of concept study after that we will do a study approved by the FDA. This is a little bit longer process with women health but we are spending a lot of money and investing in this technology.
Shakil Lakhani: And Caitlin just to add to that to what Moshe was saying, the one thing that we have noticed is that a lot of the competitors have and we’ve talked about this in the past but they’ve kind of drawn out of the market and so we do see this is a nice little opening where we’re trying to capitalize on that but again doing it the right way as Moshe had mentioned.
Caitlin Cronin: Awesome and then just a quick question on evoke, to you want the next generation of the product yet? Thank you.
Moshe Mizrahy: Yeah we developed the next generation with additional power and additional I would say energy, different energy. It’s not yet on the market. We are now finalizing the last I would say fine tune of the product. Hopefully it will go to production this quarter and we probably will launch it sometime to the end of the year.
Operator: The next question is from Jeff Johnson with Baird. Please go ahead.
Jeff Johnson: Thank you so much guys. Just maybe if I could take through two or three quick ones here. The International Unit sales at 966 number was definitely a strong number. Anything in there one time in nature you went direct and it sounds like Japan and I think you said one other market that I wrote down that I could now, but was that had — did that have any stock in order to it, were there any new distributors that had stock in or that 966 a clean number and if it is, we tend to take a fourth quarter being the peak every year should we think that you could still sell more than 966 units as we get into the fourth quarter of this year again a strong number here in the second quarter?
Moshe Mizrahy: Well the international is not one market. On the International market there are 27 languages and more than 27 regulatory bodies that we need to deal with and some claim on one country are not applicable to another country and some products need to do some modification because of regulatory issue. So the dealing with — dealing with the international market is country by country, territory by territory. We’re currently heavily investing in Asia with a lot of marketing activity and a lot of training and this is the reason why we open subsidiary in Japan because we believe Japan should be a good market for us. It’s usually a good market for medical aesthetic and our distributor in Japan they did well but not as — not according to our expectation.
